Domínguez-Escrig J L, Casanova Ramón-Borja J
Servicio de Urología. Fundación Instituto Valenciano de Oncología (I.V.O.) Valencia. España.
Arch Esp Urol. 2016 Jul;69(6):327-36.
The increase of the diagnosis of low risk prostate cancer translates into a new clinical entity, for which active surveillance may not be always enough and conventional therapies are clearly overtreatment. Faced with the necessity of giving a therapeutic answer to these patients, and facilitated by the technological advances in the imaging field and new energy sources, the interest is centered in the clinical development of focal therapies as an alternative with minimal morbidity and oncologically safe. As a part of the review carried out in this monographic issue, this article focus on the features relative to the preclinical and clinical development of laser ablative therapy and the innovative photodynamic vascular therapy with soluble TOOKAD®. With this aim we performed an exhaustive bibliographic search, updated to February 2016, in the greater databases, including original articles and reviews in reference to the object of this review, without restrictions for year of publication. This article reviews the preclinical and clinical development of these innovative ablative techniques in the field of focal therapy for low risk prostate cancer.
低风险前列腺癌诊断率的增加形成了一种新的临床实体，对于这种情况，主动监测可能并不总是足够的，而传统疗法显然属于过度治疗。面对为这些患者提供治疗方案的必要性，以及在成像领域的技术进步和新能源的推动下，人们的兴趣集中在聚焦治疗的临床开发上，将其作为一种发病率最低且肿瘤学上安全的替代方案。作为本期专题综述的一部分，本文重点关注与激光消融治疗和使用可溶性TOOKAD®的创新光动力血管治疗的临床前和临床开发相关的特征。为此，我们在包括2016年2月更新的各大数据库中进行了详尽的文献检索，包括与本综述主题相关的原创文章和综述，对发表年份没有限制。本文回顾了这些创新消融技术在低风险前列腺癌聚焦治疗领域的临床前和临床开发情况。
